Sulfur/reduced graphite oxide and dual-anion solid polymer‒electrolyte integrated structure for high-loading practical all-solid-state lithium–sulfur batteriesEun Mi Kim, Jae‐Kwang Kim, Dong‐Ho Baek et al.|NPG Asia Materials|2024Cited by 5
Patient-reported outcomes (PROs) for tivozanib (TIVO) + nivolumab (NIVO) vs TIVO monotherapy in patients with renal cell carcinoma (RCC) following an immune checkpoint inhibitor (ICI): Results of the phase 3 TiNivo-2 study.Katy Beckermann, Bradley A. McGregor, Toni K. Choueiri et al.|Journal of Clinical Oncology|2025Cited by 0
Efficacy of second line (2L) treatment with tivozanib (Tivo) as monotherapy or with nivolumab (Nivo) in patients (pts) with metastatic renal cell carcinoma (mRCC) previously treated with an immune checkpoint inhibitor (ICI) combination of ipilimumab (Ipi)/Nivo or vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI)/ICI in the phase 3 TiNivo-2 study.Alex Chehrazi‐Raffle, Toni K. Choueiri, Robert J. Motzer et al.|Journal of Clinical Oncology|2025Cited by 0